Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical study
详细信息 查看全文
- 作者：Tatsuo Furukawa (1)
Miwako Narita (2)
Tadashi Koike (3)
Kazue Takai (4)
Koichi Nagai (5)
Masashi Kobayashi (6)
Satoru Koyama (7)
Yoshinobu Seki (8)
Hoyu Takahashi (9)
Masahiro Fujiwara (10)
Kenji Kishi (6)
Koji Nikkuni (4)
Noriatsu Isahai (5)
Wataru Higuchi (11)
Nobuhiko Nomoto (12)
Souichi Maruyama (13)
Masayoshi Masuko (1)
Takashi Kuroha (14)
Takashi Abe (14)
Ken Toba (14)
Masuhiro Takahashi (2)
Yoshifusa Aizawa (14)
Akira Shibata (13) - 关键词：Real ; time quantitative polymerase chain reaction ; Molecular response ; Interphase fluorescence in situ hybridization ; Major molecular response ; Log reduction
- 刊名：International Journal of Hematology
- 出版年：2011
- 出版时间：March 2011
- 年：2011
- 卷：93
- 期：3
- 页码：336-343
- 全文大小：507KB
- 参考文献：1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-7. CrossRef
2. De Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358-3. CrossRef
3. Kantarjian H, O’Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008;112:837-5. CrossRef
4. Marin D, Milojkovic D, Olavarria E, Khorashad JS, de Lavallade H, Reid AG, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008;112:4437-4. CrossRef
5. Alvarado Y, Kantarjian H, O’Brien S, Faderl S, Borthakur G, Burger J, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009;115:3709-8. CrossRef
6. Clark RE. Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. Leuk Res. 2009;33:1151-. CrossRef
7. Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008;419-6.
8. Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica. 2008;93:161-. CrossRef
9. Reinhold U, Hennig E, Leiblein S, Niederwieser D, Deininger MW. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib. Leukemia. 2003;17:1925-. CrossRef
10. Takahashi N, Miura I, Kobayashi Y, Kume M, Yoshioka T, Otane W, et al. Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy. Int J Hematol. 2005;81:235-1. CrossRef
11. Kantarjian HM, Talpaz M, Cortes J, O’Brien S, Faderl S, Thomas D, et al. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res. 2003;9:160-.
12. Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica. 2004;89:49-7.
13. Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukemia. 2006;20:664-0. CrossRef
14. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-0. CrossRef
15. Osumi K, Fukui T, Kiyoi H, Kasai M, Kodera Y, Kudo K, et al. Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma. 2002;43:2291-. CrossRef
16. Yokota H, Tsuno NH, Tanaka Y, Fukui T, Kitamura K, Hirai H, et al. Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay. Leukemia. 2002;16:1167-5. CrossRef
17. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-2. CrossRef
18. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22:1963-. CrossRef
19. Goldman JM. Initial treatment for patients with CML. Hematology Am Soc Hematol Educ Program. 2009;453-0.
20. Kantarjian HM, Talpaz M, O’Brien S, Jones D, Giles F, Garcia-Manero G, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108:1835-0. CrossRef
21. Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006;12:3037-2. CrossRef
22. Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 2006;107:4250-. CrossRef
23. Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, et al. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin Cancer Res. 2009;15:1059-3. CrossRef
24. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-7. CrossRef
25. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time-quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia. 2003;17:2474-6. CrossRef
26. Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, et al. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate. Med Oncol. 2004;21:349-8. CrossRef - 作者单位：Tatsuo Furukawa (1)
Miwako Narita (2)
Tadashi Koike (3)
Kazue Takai (4)
Koichi Nagai (5)
Masashi Kobayashi (6)
Satoru Koyama (7)
Yoshinobu Seki (8)
Hoyu Takahashi (9)
Masahiro Fujiwara (10)
Kenji Kishi (6)
Koji Nikkuni (4)
Noriatsu Isahai (5)
Wataru Higuchi (11)
Nobuhiko Nomoto (12)
Souichi Maruyama (13)
Masayoshi Masuko (1)
Takashi Kuroha (14)
Takashi Abe (14)
Ken Toba (14)
Masuhiro Takahashi (2)
Yoshifusa Aizawa (14)
Akira Shibata (13)
1. Division of Bone Marrow Transplantation, Niigata University Medical and Dental Hospital, Asahimachi-dori 1-754, Chuoku, Niigata, 951-8520, Japan
2. Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan
3. Nagaoka Red Cross Hospital, Nagaoka, Japan
4. Niigata City General Hospital, Niigata, Japan
5. Niigata Prefectural Central Hospital, Joetsu, Japan
6. Nagaoka Chuo General Hospital, Nagaoka, Japan
7. Saiseikai Niigata Daini Hospital, Niigata, Japan
8. Niigata Prefectural Shibata Hospital, Shibata, Japan
9. Niigata Prefectural Kamo Hospital, Kamo, Japan
10. Kariwagun General Hospital, Kashiwazaki, Japan
11. Tsubame Rosai Hospital, Tsubame, Japan
12. Niigata Medical Center, Niigata, Japan
13. Niigata Minami Hospital, Niigata, Japan
14. Division of Hematology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
文摘
This retrospective analysis investigated the prognostic value of monitoring the response to imatinib using peripheral blood (PB) samples and the impact of the response on outcome in 133 patients with chronic myeloid leukemia (CML). We divided the response into 3 categories according to the results of neutrophil (N)-FISH and BCR-ABL transcript levels in PB; more than a 3-log reduction [major molecular response (MMR)], between a 2-log and 3-log reduction or negative with N-FISH [complete cytogenetic response equivalent (CCyRe)], N-FISH positive or less than a 2-log reduction (non-CCyRe). The median follow-up was 5.46?years. At 5?years, the overall survival (OS) rate and progression-free survival (PFS) rate were 94.4 and 92.0%, respectively. The estimated rate of the CCyRe and MMR were 81.7 and 67.1%, respectively. 106 patients achieving the CCyRe had significantly better OS and PFS than 27 patients without achieving the CCyRe. Patients with MMR had significantly better survival free from death, progression, imatinib withdrawal and a loss of the CCyRe, than patients whose response level remained in the CCyRe without achieving MMR until 18?months. Our observation suggests that the response level of the CCyRe on PB serve as a prognostic indicator, and achieving MMR provides stable long-term survival.